Drugs / IDX719
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01919125 | Aug 2013 → Feb 2014 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01907724 | May → Aug 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT01813513 | Jan → Jul 2013 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01508156 | Jan → Jul 2012 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-01-13 | Medivir | Results Interim results (SVR4) from a phase II all-oral combination study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C medivir.com ↗
The combination regimen of the study was well-tolerated. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-01-13 | Medivir | Interim results (SVR4) from a phase II all-oral combination study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C medivir.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IDX719 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01919125 ↗ |
| Action | Inhibit | “Samatasvir is a pan-genotypic inhibitor of the hepatitis C (HCV) non-structural protein 5A (NS5A).” PMID 24434503 ↗ Jan 2014 |
| Route | Oral | “IDX719 liquid suspension (1 - 100 mg) taken by mouth.” NCT01508156 ↗ |